

Marina I Afanasieva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5136327/publications.pdf>

Version: 2024-02-01

19
papers

76
citations

1478505

6
h-index

1474206

9
g-index

24
all docs

24
docs citations

24
times ranked

93
citing authors

#	ARTICLE	IF	CITATIONS
1	The relationship between the level of Lp(a) and the prevalence of atherosclerosis among young patients. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 479-484.	0.8	1
2	Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. <i>Biomolecules</i> , 2021, 11, 257.	4.0	6
3	Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level. <i>Journal of Cardiovascular Development and Disease</i> , 2020, 7, 45.	1.6	7
4	Association Of Lipoprotein(A) With Lower Extremity Artery Disease And Cardiovascular Outcomes After Peripheral Revascularization. <i>Atherosclerosis</i> , 2019, 287, e57-e58.	0.8	0
5	Lipoprotein (A) In Patients With Diffuse Coronary Artery Atherosclerosis. <i>Atherosclerosis</i> , 2019, 287, e229-e230.	0.8	0
6	High lipoprotein(A) level is a predictor of severe carotid atherosclerosis and ischemic stroke. <i>Atherosclerosis</i> , 2018, 275, e159.	0.8	0
7	IgM autoantibodies against lipoprotein(A) as an "anti-atherogenic" factor in patients with severe hyperlipidemia. <i>Atherosclerosis</i> , 2018, 275, e17-e18.	0.8	0
8	Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. <i>Atherosclerosis</i> , 2018, 277, 477-482.	0.8	15
9	Hyperlipoproteinemia(a) as a risk factor of coronary heart disease in patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2018, 275, e163.	0.8	0
10	High Lipoprotein(a) Level is a Predictor of Peripheral Artery Disease Regardless of the Presence of Type 2 Diabetes. <i>Atherosclerosis Supplements</i> , 2018, 32, 42.	1.2	0
11	RAISED IgM AUTOANTIBODY TITER TO LIPOPROTEIN(A) AS ANTIATHEROGENIC FACTOR IN SEVERE HYPERCHOLESTEROLEMIA PATIENTS. <i>Russian Journal of Cardiology</i> , 2018, , 13-20.	1.4	2
12	Inflammation markers in coronary heart disease patients with aortic valve stenosis. <i>Russian Journal of Cardiology</i> , 2018, , 17-22.	1.4	1
13	Lipoprotein(A) level as a discriminator of severe peripheral atherosclerosis. <i>Atherosclerosis</i> , 2017, 263, e65-e66.	0.8	1
14	Lipoprotein(a) as a predictor of severe atherosclerotic lesion after surgery on peripheral arteries. <i>Atherosclerosis</i> , 2017, 263, e208.	0.8	0
15	SUBFRACTIONS OF ATHEROGENIC APOB-LIPOPROTEIN(A) IN PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2017, 16, 45-49.	1.4	2
16	Ig apheresis for the treatment of severe DCM patients. <i>Atherosclerosis Supplements</i> , 2013, 14, 213-218.	1.2	12
17	Preparation of affinity sorbents with immobilized synthetic ligands for therapeutic apheresis. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2010, 4, 303-307.	0.4	6
18	P150 HIGH LIPOPROTEIN(A) LEVEL IS ASSOCIATED WITH POOR LONG-TERM PROGNOSIS AFTER CORONARY ARTERY BYPASS GRAFTING. <i>Atherosclerosis Supplements</i> , 2010, 11, 48.	1.2	0

#	ARTICLE	IF	CITATIONS
19	PO19-540 HIGH LIPOPROTEIN(A) LEVEL AND LOW-MOLECULAR WEIGHT APO(A) PHENOTYPES PREDISPOSE TO CORONARY OCCLUSIONS. <i>Atherosclerosis Supplements</i> , 2007, 8, 150.	1.2	0